Friday, May 25, 2018

Grail Gets $300M More For Cancer Detection Testing

Menlo Park-based Grail, which is developing DNA-based, blood testing technology to detect cancer, has raised $300M more in funding, the company said this week. The funding came from Ally Bridge Group, Hillhouse Capital, 6 Dimensions Capital, Blue Pool Capital, China Merchant Securities International, CRF Investment, HuangPu River Capital, ICBC International, Sequoia Capital China and WuXi NextCODE. The startup, led by CEO Jennifer Cook, is a spinout of Illumina. More information »